Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2601 - 2700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2601 | 26667331 |
US |
2 | |
Dry skin, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, TRALOKINUMAB-LDRM, |
||||
| 2602 | 26667337 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2603 | 26667339 |
US |
1 | |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 2604 | 26667342 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2605 | 26667345 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2606 | 26667359 |
US |
46 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2607 | 26667394 |
US |
30 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2608 | 26667413 |
US |
41 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, ETANERCEPT, |
||||
| 2609 | 26667414 |
US |
28 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2610 | 26667466 |
US |
2 | |
Erythema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2611 | 26667471 |
US |
10 | 2 |
Dermatitis atopic, Scratch, Haemorrhage, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, DESOXIMETASONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 2612 | 26667480 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2613 | 26667481 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2614 | 26667488 |
US |
53 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2615 | 26667499 |
US |
29 | 1 |
Discomfort, Insomnia, Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2616 | 26667552 |
US |
16 | 2 |
Abdominal pain upper, Eczema, Rash, Swelling face, Swelling, Ear swelling, Peripheral swelling, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2617 | 26667572 |
US |
6 | 2 |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, |
||||
| 2618 | 26667573 |
US |
1 | 2 |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, SODIUM SULFACETAMIDE, |
||||
| 2619 | 26667591 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2620 | 26667596 |
US |
2 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2621 | 26667597 |
US |
73 | 2 |
Skin irritation, Dysuria, Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 2622 | 26667598 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, INDOMETHACIN, CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, BUPROPION, FAMOTIDINE, |
||||
| 2623 | 26667609 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2624 | 26667648 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2625 | 26667863 |
US |
39 | 1 |
Tendonitis, Arthralgia, Drug hypersensitivity, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2626 | 26668738 |
US |
37 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2627 | 26668739 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2628 | 26668744 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2629 | 26668745 |
US |
24 | 2 |
Dermatitis atopic, Pruritus, Product dose omission in error, Injection site pain, |
||||
DUPILUMAB, |
||||
| 2630 | 26668748 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2631 | 26668749 |
US |
70 | 2 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 2632 | 26668758 |
US |
21 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2633 | 26668762 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2634 | 26668904 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2635 | 26668951 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2636 | 26668986 |
US |
63 | 2 |
Skin infection, Dermatitis, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2637 | 26669013 |
US |
25 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2638 | 26669014 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2639 | 26669019 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2640 | 26669100 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2641 | 26669106 |
US |
70 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2642 | 26669109 |
US |
82 | 1 |
Abnormal faeces, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2643 | 26669146 |
US |
2 | |
Dermatitis atopic, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2644 | 26669147 |
US |
31 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2645 | 26669151 |
US |
2 | 1 |
Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 2646 | 26669155 |
US |
5 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2647 | 26669159 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2648 | 26669161 |
US |
16 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2649 | 26669174 |
US |
61 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2650 | 26669183 |
US |
1 | 1 |
Pruritus, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2651 | 26669186 |
US |
60 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2652 | 26669188 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2653 | 26669194 |
US |
13 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 2654 | 26669195 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2655 | 26669198 |
US |
5 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2656 | 26669199 |
US |
49 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 2657 | 26669206 |
US |
77 | 1 |
Dermatitis atopic, Therapeutic response shortened, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 2658 | 26669210 |
US |
80 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2659 | 26669215 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2660 | 26669243 |
US |
4 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2661 | 26669245 |
US |
12 | 2 |
Dermatitis atopic, Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2662 | 26669570 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
OMALIZUMAB, EPINEPHRINE, |
||||
| 2663 | 26679752 |
85 | 1 | |
Pityriasis rosea, Body tinea, Staphylococcal skin infection, Eczema, Immune system disorder, Dermatitis contact, Eczema nummular, Dermatitis atopic, Dermatitis allergic, Drug eruption, |
||||
| 2664 | 26657941 |
US |
66 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2665 | 26657951 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2666 | 26657965 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2667 | 26657985 |
US |
31 | 2 |
Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 2668 | 26658053 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2669 | 26658058 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2670 | 26658066 |
US |
6 | 1 |
Dermatitis atopic, Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 2671 | 26658079 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2672 | 26658107 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2673 | 26658116 |
US |
33 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2674 | 26658160 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2675 | 26658165 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2676 | 26658174 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2677 | 26658215 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2678 | 26658246 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, Eye swelling, Product dose omission issue, |
||||
DUPILUMAB, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, DIPHENHYDRAMINE HYDROCHLORIDE, DIAZEPAM, VITAMIN C, VITAMIN E, |
||||
| 2679 | 26658247 |
US |
20 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, BUPROPION HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, |
||||
| 2680 | 26658279 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2681 | 26658332 |
US |
34 | 2 |
Injection site pain, Injection site erythema, Accidental exposure to product, Exposure via skin contact, Dermatitis atopic, Eczema, Acne, Body tinea, Dry skin, Skin exfoliation, Skin warm, Pain of skin, Scab, Skin induration, Pruritus, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2682 | 26658348 |
US |
54 | 1 |
Discomfort, Sleep disorder due to a general medical condition, Memory impairment, Rash, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, MIRTAZAPINE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREGABALIN, RAMELTEON, ROSUVASTATIN, EZETIMIBE, HYOSCYAMINE SULFATE, NIFEDIPINE, |
||||
| 2683 | 26658352 |
US |
60 | 1 |
Dermatitis atopic, Product dose omission issue, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, CLOPIDOGREL, CLOPIDOGREL BISULFATE, NITROGLYCERIN, RANOLAZINE, EVOLOCUMAB, |
||||
| 2684 | 26658423 |
US |
2 | |
Dermatitis atopic, Injection site pain, |
||||
DUPILUMAB, |
||||
| 2685 | 26658531 |
US |
1 | |
Dermatitis atopic, Injection site pain, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, METHOCARBAMOL, METHOCARBAMOL TABLETS, TIRZEPATIDE, ROSUVASTATIN CALCIUM, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ERGOCALCIFEROL, |
||||
| 2686 | 26658845 |
US |
70 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2687 | 26658852 |
US |
55 | 2 |
Cough, Dermatitis atopic, Scratch, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2688 | 26658855 |
US |
60 | 2 |
Urticaria, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2689 | 26658914 |
US |
10 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2690 | 26658919 |
US |
40 | 1 |
Dermatitis atopic, Pruritus, Erythema, Rash macular, Product dose omission issue, |
||||
DUPILUMAB, TRALOKINUMAB-LDRM, |
||||
| 2691 | 26658922 |
US |
17 | 2 |
Dermatitis atopic, Ocular hyperaemia, Rash, Pruritus, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2692 | 26658969 |
US |
44 | 2 |
Photosensitivity reaction, Condition aggravated, Pruritus, Rash, Dermatitis atopic, Product dose omission issue, Injection site pruritus, Injection site inflammation, Skin disorder, Product administered at inappropriate site, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2693 | 26658970 |
US |
57 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2694 | 26658971 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2695 | 26658982 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2696 | 26658991 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2697 | 26658995 |
US |
56 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2698 | 26659029 |
US |
69 | 1 |
Dermatitis atopic, Pustule, Dry skin, Scab, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2699 | 26659041 |
US |
4 | 2 |
Dermatitis atopic, Nasopharyngitis, |
||||
DUPILUMAB, |
||||
| 2700 | 26659045 |
US |
4 | 1 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30